Redmond WL - Search Results

1

Current Clinical Trial Landscape of OX40 Agonists.

Yadav R, Redmond WL. Yadav R, et al. Among authors: redmond wl. Curr Oncol Rep. 2022 Jul;24(7):951-960. doi: 10.1007/s11912-022-01265-5. Epub 2022 Mar 29. Curr Oncol Rep. 2022. PMID: 35352295 Review.

2

Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.

Redmond WL, Weinberg AD. Redmond WL, et al. Crit Rev Immunol. 2007;27(5):415-36. doi: 10.1615/critrevimmunol.v27.i5.20. Crit Rev Immunol. 2007. PMID: 18197805 Review.

3

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. Gough MJ, et al. Among authors: redmond wl. Cancer Res. 2008 Jul 1;68(13):5206-15. doi: 10.1158/0008-5472.CAN-07-6484. Cancer Res. 2008. PMID: 18593921 Free article.

4

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.

Redmond WL, Gough MJ, Weinberg AD. Redmond WL, et al. Eur J Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348. Eur J Immunol. 2009. PMID: 19672905 Free PMC article.

5

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD. Gough MJ, et al. Among authors: redmond wl. J Immunother. 2010 Oct;33(8):798-809. doi: 10.1097/CJI.0b013e3181ee7095. J Immunother. 2010. PMID: 20842057 Free PMC article.

6

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA. Jensen SM, et al. Among authors: redmond wl. Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Semin Oncol. 2010. PMID: 21074068 Free PMC article. Review.

7

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.

Redmond WL, Triplett T, Floyd K, Weinberg AD. Redmond WL, et al. PLoS One. 2012;7(4):e34467. doi: 10.1371/journal.pone.0034467. Epub 2012 Apr 4. PLoS One. 2012. PMID: 22496812 Free PMC article.

8

Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Redmond WL, Linch SN, Kasiewicz MJ. Redmond WL, et al. Cancer Immunol Res. 2014 Feb;2(2):142-53. doi: 10.1158/2326-6066.CIR-13-0031-T. Epub 2013 Nov 11. Cancer Immunol Res. 2014. PMID: 24778278 Free PMC article.

9

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

Linch SN, McNamara MJ, Redmond WL. Linch SN, et al. Among authors: redmond wl. Front Oncol. 2015 Feb 16;5:34. doi: 10.3389/fonc.2015.00034. eCollection 2015. Front Oncol. 2015. PMID: 25763356 Free PMC article. Review.

10

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.

Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL. Linch SN, et al. Among authors: redmond wl. Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E319-27. doi: 10.1073/pnas.1510518113. Epub 2016 Jan 4. Proc Natl Acad Sci U S A. 2016. PMID: 26729864 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page